Table 3.
Time Postexposure |
|||||||
---|---|---|---|---|---|---|---|
Cytokine Category | Cytokine | Region | Day 1 | Day 3 | Day 7 | Day 14 | Day 28 |
Chemotactic | MIP-1aa | All | ↑ | ↑ | ↑ | ↑ | ↑ |
MCP-1b | HP | ↑ | ↑ | ↑ | ns | ↑ | |
PC | ↑ | ↑ | ↑ | ↓ | ns | ||
MIP-3aa | All | ↑ | ↓ | ns | ns | ns | |
GRO/KCb | HP | ↑ | ns | ns | ns | ns | |
PC | ↑ | ns | ns | ↓ | ns | ||
RANTESc | All | ↓ | |||||
VEGFc | All | ↓ | |||||
Antiinflammatory | IL-4a | All | ns | ↓ | ns | ↓ | ns |
IL-5a | All | ↓ | ↓ | ns | ↓ | ns | |
IL-10d | HP | ↓ | |||||
PC | ns | ||||||
IL-13a | All | ↓ | ↓ | ns | ↓ | ns | |
Pleiotropic pro- and antiinflammatory | IL-2c | All | ns | ||||
IL-7c | All | ↓ | |||||
IL-12(p70)c | All | ↓ | |||||
Proinflammatory | IL-1αa | All | ns | ↓ | ns | ↓ | ns |
IL-1βd | HP | ↓ | |||||
PC | ns | ||||||
IL-6c | All | ↓ | |||||
IL-17a | All | ↓ | ↓ | ns | ↓ | ns | |
IL-18d | HP | ↓ | |||||
PC | ns | ||||||
M-CSFc | All | ↓ | |||||
G-CSFa | All | ns | ↓ | ns | ns | ns | |
GM-CSFc | All | ↓ | |||||
IFN-γa | All | ↓ | ↓ | ns | ↓ | ns | |
TNF-αd | HP | ↓ | |||||
PC | ↓ |
↓ indicates levels are lower in DFP (n = 6–9 per group) compared with VEH (n = 3-4 per group), ↑ indicates levels are higher in DFP compared with VEH, and “ns” (light gray) indicates no significant difference between groups. Only differences that remained significant after an FDR correction are presented.
Abbreviations: All, pooled across brain regions; HP, hippocampus; PC, piriform cortex.
Interaction between day and treatment, significant differences are presented by day.
Both day by treatment and region by treatment interactions, significant differences are presented by region by day.
No interactions between treatment and another factor, the global difference between DFP and VEH are presented.
Interaction between region and treatment, significant differences are presented by region.